And just this month, the federal Food and Drug Administration requested Endo Pharmaceuticals, an international pharmaceutical
manufacturer, remove Opana ER — a semi-synthetic
opioid painkiller — from the market
after concluding the drug's potential for abuse outweighed its therapeutic value.